Reni Benjamin
Stock Analyst at Citizens
(1.48)
# 3,547
Out of 5,182 analysts
165
Total ratings
39.13%
Success rate
-10.71%
Average return
Main Sectors:
Stocks Rated by Reni Benjamin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IMMP Immutep | Downgrades: Market Perform | n/a | $0.52 | - | 1 | Mar 13, 2026 | |
| IMMX Immix Biopharma | Initiates: Market Outperform | $23 | $9.53 | +141.34% | 1 | Mar 9, 2026 | |
| ALLO Allogene Therapeutics | Upgrades: Market Outperform | $5 | $2.25 | +122.22% | 9 | Jan 9, 2026 | |
| CMPX Compass Therapeutics | Initiates: Market Outperform | $10 | $1.79 | +458.66% | 1 | Dec 3, 2025 | |
| BCYC Bicycle Therapeutics | Maintains: Market Outperform | $10 → $12 | $4.77 | +151.57% | 15 | Oct 31, 2025 | |
| INBX Inhibrx Biosciences | Reiterates: Market Perform | n/a | $131.45 | - | 10 | May 15, 2025 | |
| CUE Cue Biopharma | Reiterates: Market Outperform | $60 | $17.93 | +234.63% | 5 | Apr 2, 2025 | |
| BCAB BioAtla | Maintains: Market Outperform | $250 → $50 | $4.51 | +1,008.65% | 9 | Mar 31, 2025 | |
| INCY Incyte | Reiterates: Market Perform | n/a | $95.72 | - | 28 | Mar 11, 2025 | |
| ACET Adicet Bio | Reiterates: Market Perform | n/a | $7.93 | - | 5 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $12 → $4 | $0.83 | +381.93% | 5 | Jan 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $8 → $4 | $2.92 | +36.99% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.47 | - | 2 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $7.97 | - | 3 | Jun 14, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $10 | $10.93 | -8.51% | 2 | Oct 12, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $3 → $6 | $4.52 | +32.74% | 6 | Mar 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Outperform | $23 | $33.59 | -31.53% | 11 | Jan 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $5 | $3.26 | +53.37% | 6 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $28 | $9.07 | +208.71% | 11 | Jun 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $8.13 | - | 2 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $40 | $22.12 | +80.83% | 4 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $3.43 | - | 11 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $7 → $8 | $13.22 | -39.49% | 1 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $60 | $45.28 | +32.51% | 1 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $9.37 | - | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $315 | $117.83 | +167.33% | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $76.27 | - | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $265 | $222.19 | +19.27% | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $28 → $17 | $3.76 | +352.13% | 3 | Nov 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | n/a | $8.62 | - | 4 | Jun 14, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Perform | n/a | $3.05 | - | 2 | Feb 7, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $22 → $12 | $35.38 | -66.08% | 1 | Sep 25, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $23.77 | - | 1 | Nov 15, 2017 |
Immutep
Mar 13, 2026
Downgrades: Market Perform
Price Target: n/a
Current: $0.52
Upside: -
Immix Biopharma
Mar 9, 2026
Initiates: Market Outperform
Price Target: $23
Current: $9.53
Upside: +141.34%
Allogene Therapeutics
Jan 9, 2026
Upgrades: Market Outperform
Price Target: $5
Current: $2.25
Upside: +122.22%
Compass Therapeutics
Dec 3, 2025
Initiates: Market Outperform
Price Target: $10
Current: $1.79
Upside: +458.66%
Bicycle Therapeutics
Oct 31, 2025
Maintains: Market Outperform
Price Target: $10 → $12
Current: $4.77
Upside: +151.57%
Inhibrx Biosciences
May 15, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $131.45
Upside: -
Cue Biopharma
Apr 2, 2025
Reiterates: Market Outperform
Price Target: $60
Current: $17.93
Upside: +234.63%
BioAtla
Mar 31, 2025
Maintains: Market Outperform
Price Target: $250 → $50
Current: $4.51
Upside: +1,008.65%
Incyte
Mar 11, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $95.72
Upside: -
Adicet Bio
Mar 7, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $7.93
Upside: -
Jan 14, 2025
Maintains: Market Outperform
Price Target: $12 → $4
Current: $0.83
Upside: +381.93%
Aug 8, 2022
Maintains: Market Outperform
Price Target: $8 → $4
Current: $2.92
Upside: +36.99%
Dec 3, 2019
Downgrades: Market Perform
Price Target: n/a
Current: $1.47
Upside: -
Jun 14, 2019
Reinstates: Market Perform
Price Target: n/a
Current: $7.97
Upside: -
Oct 12, 2018
Maintains: Outperform
Price Target: $11 → $10
Current: $10.93
Upside: -8.51%
Mar 11, 2026
Maintains: Market Outperform
Price Target: $3 → $6
Current: $4.52
Upside: +32.74%
Jan 20, 2026
Upgrades: Market Outperform
Price Target: $23
Current: $33.59
Upside: -31.53%
Jun 24, 2025
Reiterates: Market Outperform
Price Target: $5
Current: $3.26
Upside: +53.37%
Jun 4, 2025
Reiterates: Market Outperform
Price Target: $28
Current: $9.07
Upside: +208.71%
Jun 2, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $8.13
Upside: -
Jun 2, 2025
Reiterates: Market Outperform
Price Target: $40
Current: $22.12
Upside: +80.83%
May 9, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $3.43
Upside: -
Mar 12, 2025
Maintains: Market Outperform
Price Target: $7 → $8
Current: $13.22
Upside: -39.49%
Mar 3, 2025
Reiterates: Market Outperform
Price Target: $60
Current: $45.28
Upside: +32.51%
Feb 6, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $9.37
Upside: -
Feb 6, 2025
Reiterates: Market Outperform
Price Target: $315
Current: $117.83
Upside: +167.33%
Feb 6, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $76.27
Upside: -
Feb 6, 2025
Reiterates: Market Outperform
Price Target: $265
Current: $222.19
Upside: +19.27%
Nov 10, 2020
Downgrades: Outperform
Price Target: $28 → $17
Current: $3.76
Upside: +352.13%
Jun 14, 2019
Reinstates: Outperform
Price Target: n/a
Current: $8.62
Upside: -
Feb 7, 2019
Upgrades: Market Perform
Price Target: n/a
Current: $3.05
Upside: -
Sep 25, 2018
Downgrades: Outperform
Price Target: $22 → $12
Current: $35.38
Upside: -66.08%
Nov 15, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $23.77
Upside: -